Established in 2020 Saturday, January 16, 2021


New project aims to develop a new treatment option for brain cancer
Scanning electron micrograph of brain cancer stem cells exposed to a carbon-type nanocarriers (cancer stem cell body (blue), nucleus (pink), nanocarriers (yellow). Image courtesy: King's College London.



LONDON.- Brain cancer remains one of the hardest diseases to treat in the history of oncology with a median patient survival of 12-15 months after diagnosis. The current treatments including surgical resection followed by radio/chemotherapy prolong survival, however a cure has not yet been found.

This project aims to develop a new treatment option for brain cancer by using a class of chemotherapeutic drugs known for their ability to trigger a specific mechanism of cell death, referred to as immunogenic cell death (ICD). Further, in combination with ICD, researchers working on this project aim to use gene silencing approaches to reduce the presence of a ‘don’t eat me’ CD47 protein receptor which cancer cells use to escape clearance by immune cells.

This 3-year project “Can immunogenic cell death be exploited in brain cancer?”, funded by Brain Research UK, is a cross-School collaboration between Professor Khuloud Al-Jamal, Dr Julie Wang, Dr Adam Walters and Dr James Arnold as co-investigators. The awarding panel noted the strength of the multi-disciplinary team.




"Collectively there is a wealth of expertise on brain drug delivery, cancer immunology and clinical translation within our research team and collaborators within the institution and externally. The awarding panel clearly appreciated that the project is highly significant and innovative, and the success of the study will bring a new paradigm in brain tumour treatment." – Professor Khuloud Al-Jamal, School of Cancer & Pharmaceutical Sciences

The research proposal builds on the team’s recent efforts to identify novel targets in glioblastoma and cancer stem cells and develop new approaches for in situ cancer vaccination funded by Wellcome Trust, Brain Tumour Charity, and British Council. Professor Al-Jamal is a steering committee member of the Children Brain Tumour Drug Delivery Consortium.

"This project aims to develop a new combinatory treatment approach for brain tumours exploiting the therapeutic synergy between immunogenic cell death (ICD) and blockade of immune checkpoint regulator CD47. In this proposal, we would like to investigate whether ICD immunochemotherapy involving concurrent alleviation of immunosuppression can provide more effective and long-term therapeutic outcomes for brain cancer." – Professor Khuloud Al-Jamal, School of Cancer & Pharmaceutical Sciences

The proposed ‘ICD immunochemotherapy’ will be assessed in cell lines, animals, as well as clinical patients’ samples provided by Professor Keyoumars Ashkan, the lead for neuro-oncology and the neuroscience commercial clinical trial unit at King's College Hospital.







Today's News

November 23, 2020

Remains of two victims of 79 AD volcanic eruption unearthed at Pompeii

Climate change devastated dinosaurs not once, but twice

Deep learning helps robots grasp and move objects with ease

Fish carcasses deliver toxic mercury pollution to the deepest ocean trenches

US approves Regeneron antibody treatment given to Trump

Researchers find that a type of RNA monitors the genome to help ensure its integrity

Zebra finches amazing at unmasking the bird behind the song

Kyoto University's seemingly random photonic crystals greatly improve laser scanning

Biofriendly protocells pump up blood vessels

New process narrows the gap between natural and synthetic materials

Energy drinks can raise stillbirth risk and caffeine guidance confuses mums-to-be, new research warns

New project aims to develop a new treatment option for brain cancer

Sugar work: U-M study finds sugar remodels molecular memory in fruit flies

New found ability to change baby brain activity could lead to rehabilitation for injured brains, say researchers

The immune system and stem cells join forces to repair your teeth

Biologists at U of T and University of Illinois shed light on how microbes evolve and affect hosts

NASA, US and European partners launch mission to monitor global ocean

Can animals use iridescent colours to communicate?



 


Editor & Publisher: Jose Villarreal
Art Director: Juan José Sepúlveda Ramírez



Tell a Friend
Dear User, please complete the form below in order to recommend the ResearchNews newsletter to someone you know.
Please complete all fields marked *.
Sending Mail
Sending Successful